Last reviewed · How we verify
NCT04800107
Effect of Highly Bioavailable Curcumin on Subjective Tinnitus
NA trial testing Curcumin-phosphatidylcholine in Tinnitus, Subjective in 110 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | Henry Ford Health System |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 110 |
| Start date | 6 January 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Curcumin-phosphatidylcholine — full drug profile →
- Placebo capsule
Conditions studied
- Tinnitus, Subjective — all drugs for Tinnitus, Subjective →
Sponsor
Henry Ford Health System — full company profile →
Who can join
Adults 18 to 99, any sex, with Tinnitus, Subjective. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the effectiveness of highly bioavailable curcumin in suppressing subjective tinnitus based on pre- and post-treatment evaluations using the validated Tinnitus Functional Index (TFI) and Tinnitus Handicap Inventory (THI) surveys.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment.
Yang X, Liu Y, Cao J, Wu C, et al · · 2025 · cited 42× · PMID 40258841 · DOI 10.1038/s41420-025-02491-z
Verify or expand the search:
- PubMed search for NCT04800107
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tinnitus, Subjective
Currently open trials in the same condition.
- NCT07393880 — Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus · NA · recruiting
- NCT07071480 — Noninvasive Therapy for Tinnitus · NA · recruiting
- NCT07017998 — External Therapy for Tinnitus Management · NA · recruiting
- NCT06880367 — Neuromodulatory Effects of Audio-proprio-phonatory Reinforcement Training on Subjective Tinnitus, Demonstrated by High-d · NA · recruiting
- NCT06782308 — Tinnitus Patient Preferences Survey · recruiting
Other Henry Ford Health System trials
Trials by the same sponsor.
- NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
- NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
- NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
- NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
- NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04800107 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
- Last refreshed: 20 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04800107.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing